Chronic Paediatric Conditions — MCQs
On this page
A 16-year-old girl with type 1 diabetes for 9 years presents with a 4-month history of episodic dizziness on standing, particularly in the morning. She reports her heart races when she stands up. Lying blood pressure is 105/65 mmHg with heart rate 72 bpm; after standing for 3 minutes, blood pressure is 100/68 mmHg with heart rate 110 bpm. Her HbA1c is 78 mmol/mol. Examination reveals reduced sensation to light touch in both feet in a stocking distribution. What is the most likely underlying pathophysiological mechanism for her symptoms?
A 4-year-old boy with epilepsy has been taking phenobarbital for 18 months following several generalized tonic-clonic seizures. His seizures are now well-controlled but his parents and nursery staff report significant behavioural changes including hyperactivity, aggression, and poor concentration affecting his development. What property of phenobarbital best explains these adverse behavioural effects?
A 10-year-old boy with refractory epilepsy is being considered for vagus nerve stimulation (VNS) therapy. Despite trials of multiple anti-epileptic drugs, he continues to have 3-4 focal seizures with impaired awareness per week significantly impacting his quality of life. MRI brain shows no structural lesion amenable to surgical resection. His parents ask about the expected benefit of VNS. What is the most accurate statement regarding efficacy of VNS therapy in paediatric epilepsy?
A 15-year-old girl with type 1 diabetes for 8 years attends for routine screening. She is found to have background diabetic retinopathy with several microaneurysms and dot haemorrhages in both eyes but no other features. Her HbA1c is 68 mmol/mol and blood pressure is 118/72 mmHg. Visual acuity is normal at 6/6 bilaterally. What is the most appropriate management plan for her retinopathy?
A 7-year-old girl presents with episodes witnessed by her teacher where she suddenly stops talking, stares blankly for about 10 seconds with subtle eye blinking, then immediately continues her previous activity with no awareness of the episode. These occur multiple times daily. An EEG is performed showing generalized 3 Hz spike-and-wave discharges with hyperventilation provocation testing reproducing a typical episode. What underlying mechanism explains why hyperventilation provokes these seizures?
A 12-year-old boy with type 1 diabetes for 5 years presents to clinic. His HbA1c has risen from 58 mmol/mol to 74 mmol/mol over the past 6 months despite no reported changes in his insulin regimen or diet. His parents mention he has become more self-conscious about injecting insulin at school and with friends. He appears withdrawn during the consultation. What is the most important factor to explore in this clinical scenario?
An 8-year-old girl with epilepsy has been taking sodium valproate for 2 years with excellent seizure control. Her parents bring her to clinic reporting that she has gained 8 kg in weight over the past year, developed increased facial hair, and her scalp hair has become noticeably thinner. Blood tests show normal liver function and full blood count. What is the most appropriate management approach?
What is the recommended target HbA1c for children and young people with type 1 diabetes according to NICE guidelines?
A 5-year-old boy with newly diagnosed epilepsy presents to the emergency department with a continuous tonic-clonic seizure lasting 35 minutes. He has received two doses of buccal midazolam (10 mg) by paramedics 10 minutes apart without effect, and one dose of intravenous lorazepam (0.1 mg/kg) 8 minutes ago which also failed to terminate the seizure. Intravenous access is secure. What is the most appropriate next pharmacological intervention?
A 14-year-old girl with type 1 diabetes for 6 years presents for annual screening. She is on a basal-bolus regimen with good glycaemic control (HbA1c 52 mmol/mol). Screening reveals an albumin:creatinine ratio (ACR) of 3.5 mg/mmol on a random urine sample. She is asymptomatic and has normal blood pressure. What is the most appropriate next step in management?
Chronic Paediatric Conditions UK Medical PG Practice Questions and MCQs
Question 41: A 16-year-old girl with type 1 diabetes for 9 years presents with a 4-month history of episodic dizziness on standing, particularly in the morning. She reports her heart races when she stands up. Lying blood pressure is 105/65 mmHg with heart rate 72 bpm; after standing for 3 minutes, blood pressure is 100/68 mmHg with heart rate 110 bpm. Her HbA1c is 78 mmol/mol. Examination reveals reduced sensation to light touch in both feet in a stocking distribution. What is the most likely underlying pathophysiological mechanism for her symptoms?
- A. Impaired baroreceptor sensitivity with reduced sympathetic vasoconstrictor response (Correct Answer)
- B. Reduced circulating blood volume from poor glycaemic control causing dehydration
- C. Adrenal insufficiency from autoimmune polyglandular syndrome
- D. Postural orthostatic tachycardia syndrome (POTS) unrelated to diabetes
- E. Cardiac autonomic neuropathy with impaired cardiac output on standing
Explanation: ***Impaired baroreceptor sensitivity with reduced sympathetic vasoconstrictor response*** - The patient exhibits features of **diabetic autonomic neuropathy**, where damaged nerves fail to trigger the necessary **sympathetic vasoconstriction** required to maintain blood pressure upon standing. - Reduced **baroreceptor sensitivity** leads to postural dizziness; the observed **compensatory tachycardia** (heart rate increase >38 bpm) indicates that while the vascular response is impaired, the cardiac sympathetic reflex is still partially active. *Reduced circulating blood volume from poor glycaemic control causing dehydration* - While **osmotic diuresis** from high glucose levels can cause dehydration, it usually presents with more acute systemic symptoms rather than a 4-month episodic postural pattern. - The presence of **stocking-distribution sensory loss** strongly favors a chronic neuroopathic etiology, specifically **diabetic neuropathy**, over simple volume depletion. *Adrenal insufficiency from autoimmune polyglandular syndrome* - **Adrenal insufficiency** typically presents with significant **hyponatremia**, hyperkalemia, and skin hyperpigmentation, which are not mentioned here. - In this condition, one would expect a more profound decrease in **blood pressure** and systemic fatigue rather than isolated postural symptoms alongside peripheral nerve damage. *Postural orthostatic tachycardia syndrome (POTS) unrelated to diabetes* - **POTS** is characterized by a heart rate increase of >40 bpm in adolescents without a significant drop in **blood pressure** (orthostatic hypotension). - This patient's long-standing **Type 1 Diabetes** and concurrent **peripheral neuropathy** make diabetic complications a significantly more likely cause than a primary POTS diagnosis. *Cardiac autonomic neuropathy with impaired cardiac output on standing* - **Cardiac autonomic neuropathy** usually manifests as a **fixed heart rate** or a blunt tachycardic response due to vagal and sympathetic denervation. - In this case, the heart rate increases significantly from 72 to 110 bpm, suggesting that **cardiac output** compensation is attempting to occur, despite the failure of the peripheral vasculature.
Question 42: A 4-year-old boy with epilepsy has been taking phenobarbital for 18 months following several generalized tonic-clonic seizures. His seizures are now well-controlled but his parents and nursery staff report significant behavioural changes including hyperactivity, aggression, and poor concentration affecting his development. What property of phenobarbital best explains these adverse behavioural effects?
- A. Inhibition of GABA reuptake causing paradoxical excitation in children
- B. Enhancement of GABAergic transmission affecting frontal lobe executive function (Correct Answer)
- C. Induction of hepatic enzymes affecting neurotransmitter metabolism
- D. Blockade of NMDA receptors impairing cognitive development
- E. Dopamine antagonism in the prefrontal cortex
Explanation: ***Enhancement of GABAergic transmission affecting frontal lobe executive function***- Phenobarbital acts as an allosteric modulator of **GABA-A receptors**, increasing the duration of chloride channel opening to suppress seizures.- In pediatric patients, this widespread enhancement can disrupt **frontal lobe function**, leading to **paradoxical hyperactivity**, aggression, and impaired executive control.*Inhibition of GABA reuptake causing paradoxical excitation in children*- Phenobarbital enhances the **postsynaptic response** to GABA; it does not inhibit the **GAT-1 transporter** responsible for GABA reuptake.- While "paradoxical excitation" describes the clinical observation, the underlying mechanism is receptor modulation rather than **reuptake inhibition**.*Induction of hepatic enzymes affecting neurotransmitter metabolism*- Phenobarbital is a potent inducer of the **CYP450 enzyme system**, primarily affecting the metabolism of other medications and endogenous steroids.- While enzyme induction causes many **drug-drug interactions**, it is not the primary mechanism behind the **behavioral and cognitive** side effects seen in children.*Blockade of NMDA receptors impairing cognitive development*- **NMDA receptor** antagonism is more characteristic of medications like ketamine or certain effects of felbamate, rather than barbiturates.- Although high doses may have mild effects on various ion channels, the primary sedative and behavioral profile is driven by **GABAergic** rather than **glutamatergic** pathways.*Dopamine antagonism in the prefrontal cortex*- Dopamine antagonism is the hallmark mechanism of **antipsychotic medications**, not barbiturate anticonvulsants.- Phenobarbital lacks significant affinity for **D2 receptors**, and its behavioral side effects are distinct from the extrapyramidal or sedative effects of dopamine blockade.
Question 43: A 10-year-old boy with refractory epilepsy is being considered for vagus nerve stimulation (VNS) therapy. Despite trials of multiple anti-epileptic drugs, he continues to have 3-4 focal seizures with impaired awareness per week significantly impacting his quality of life. MRI brain shows no structural lesion amenable to surgical resection. His parents ask about the expected benefit of VNS. What is the most accurate statement regarding efficacy of VNS therapy in paediatric epilepsy?
- A. Complete seizure freedom is achieved in approximately 60% of patients within 12 months
- B. 50% or greater reduction in seizure frequency is achieved in approximately 50% of patients (Correct Answer)
- C. VNS is only effective for generalized epilepsies, not focal seizures
- D. Maximum benefit is seen immediately after device implantation
- E. VNS works by directly suppressing epileptogenic foci through electrical inhibition
Explanation: ***50% or greater reduction in seizure frequency is achieved in approximately 50% of patients*** - This describes the typical efficacy of VNS therapy, often referred to as the **"50-50 rule"**, which means approximately half of patients experience at least a 50% reduction in seizure frequency. - This level of reduction, while not complete freedom, significantly improves **quality of life** and reduces seizure burden in patients with **drug-resistant epilepsy**. *Complete seizure freedom is achieved in approximately 60% of patients within 12 months* - **Complete seizure freedom** with VNS is rare, occurring in only a small minority of patients (typically less than 10%). - A 60% rate of seizure freedom is more aligned with outcomes from successful **resective epilepsy surgery**, not VNS. *VNS is only effective for generalized epilepsies, not focal seizures* - VNS is **FDA-approved and effective for both focal and generalized epilepsy syndromes**, particularly in cases of **drug-resistant epilepsy**. - This patient presents with **focal seizures**, for which VNS is a recognized treatment option when surgical resection is not feasible. *Maximum benefit is seen immediately after device implantation* - The efficacy of VNS typically **increases over time**, with clinical improvements often observed gradually over several months to years (up to 12-24 months). - This **delayed response** is characteristic of its neuromodulatory mechanism, which involves long-term changes in brain activity rather than immediate suppression. *VNS works by directly suppressing epileptogenic foci through electrical inhibition* - VNS modulates brain activity via **vagal afferents** to the **nucleus tractus solitarius**, influencing widespread thalamocortical networks. - It does not directly target or electrically inhibit specific **epileptogenic foci**, but rather exerts a broader neuromodulatory effect on seizure networks.
Question 44: A 15-year-old girl with type 1 diabetes for 8 years attends for routine screening. She is found to have background diabetic retinopathy with several microaneurysms and dot haemorrhages in both eyes but no other features. Her HbA1c is 68 mmol/mol and blood pressure is 118/72 mmHg. Visual acuity is normal at 6/6 bilaterally. What is the most appropriate management plan for her retinopathy?
- A. Urgent referral to ophthalmology for laser photocoagulation
- B. Commence anti-VEGF intravitreal injections
- C. Optimize glycaemic and blood pressure control with continued annual screening (Correct Answer)
- D. Increase screening frequency to 6-monthly intervals
- E. Start fenofibrate therapy to slow retinopathy progression
Explanation: ***Optimize glycaemic and blood pressure control with continued annual screening*** - The patient has **background diabetic retinopathy** (R1), indicated by **microaneurysms** and **dot haemorrhages** with normal visual acuity, signifying no maculopathy or proliferative changes. - At this stage, the primary management is to **optimize glycaemic control** (HbA1c 68 mmol/mol is elevated) and **blood pressure** to prevent progression, with **annual screening** being appropriate. *Urgent referral to ophthalmology for laser photocoagulation* - **Laser photocoagulation** is reserved for advanced stages like **proliferative diabetic retinopathy** (neovascularization) or significant macular edema. - This patient has **background retinopathy** without maculopathy or proliferative features, which does not warrant urgent laser treatment. *Commence anti-VEGF intravitreal injections* - **Anti-VEGF intravitreal injections** are indicated for **diabetic macular oedema** or advanced proliferative retinopathy. - The patient's **normal visual acuity (6/6)** and absence of other severe features rule out significant macular edema or active proliferation requiring anti-VEGF. *Increase screening frequency to 6-monthly intervals* - **Increased screening frequency** to 6-monthly intervals is usually recommended for **pre-proliferative retinopathy** (R2), which includes features like cotton wool spots or venous beading. - For mild **background diabetic retinopathy** (R1) without maculopathy, **annual screening** is the standard recommendation. *Start fenofibrate therapy to slow retinopathy progression* - **Fenofibrate therapy** has been studied for slowing retinopathy progression in adults but is **not a standard treatment** in paediatric populations for diabetic retinopathy. - The primary management for this patient remains **tight glycaemic and blood pressure control**, rather than initiating fenofibrate.
Question 45: A 7-year-old girl presents with episodes witnessed by her teacher where she suddenly stops talking, stares blankly for about 10 seconds with subtle eye blinking, then immediately continues her previous activity with no awareness of the episode. These occur multiple times daily. An EEG is performed showing generalized 3 Hz spike-and-wave discharges with hyperventilation provocation testing reproducing a typical episode. What underlying mechanism explains why hyperventilation provokes these seizures?
- A. Hyperventilation induces anxiety which triggers absence seizures through stress hormones
- B. Hyperventilation causes cerebral hypoxia triggering neuronal hyperexcitability
- C. Reduced cerebral blood flow from hypocapnia lowers seizure threshold in susceptible individuals (Correct Answer)
- D. Alkalosis from hyperventilation directly depolarizes thalamocortical neurons
- E. Increased oxygen delivery enhances metabolic activity in epileptogenic foci
Explanation: ***Reduced cerebral blood flow from hypocapnia lowers seizure threshold in susceptible individuals***- Hyperventilation leads to **hypocapnia** (low CO2), which causes potent **cerebral vasoconstriction** and a subsequent reduction in **cerebral blood flow**.- This physiological shift affects the **thalamocortical circuits**, facilitating the characteristic **3 Hz spike-and-wave discharges** seen in childhood absence epilepsy.*Hyperventilation induces anxiety which triggers absence seizures through stress hormones*- Absence seizures are **neurological events** triggered by physiological changes, not primarily by psychological stress or corticosteroids.- While stress can be a non-specific trigger for many seizure types, it is not the mechanism behind **hyperventilation provocation** tests.*Hyperventilation causes cerebral hypoxia triggering neuronal hyperexcitability*- Hyperventilation actually maintains or slightly increases **arterial oxygen** levels; there is no systemic **hypoxia** involved.- The seizure is triggered by the **metabolic shift** and vasoconstriction related to carbon dioxide levels, not a lack of oxygen delivery.*Alkalosis from hyperventilation directly depolarizes thalamocortical neurons*- Respiratory **alkalosis** does occur during hyperventilation, but it primarily affects ionized **calcium levels**, which can increase excitability but is not the primary mechanism for absence induction.- The classic provocation in absence epilepsy is more specifically linked to the **vascular and metabolic response** to low CO2 rather than direct pH-induced depolarization.*Increased oxygen delivery enhances metabolic activity in epileptogenic foci*- Hyperventilation actually results in **decreased oxygen delivery** to the brain because vasoconstriction reduces the total volume of blood reaching the tissue.- Absence seizures involve **generalized** thalamocortical networks rather than localized **epileptogenic foci** seen in focal epilepsies.
Question 46: A 12-year-old boy with type 1 diabetes for 5 years presents to clinic. His HbA1c has risen from 58 mmol/mol to 74 mmol/mol over the past 6 months despite no reported changes in his insulin regimen or diet. His parents mention he has become more self-conscious about injecting insulin at school and with friends. He appears withdrawn during the consultation. What is the most important factor to explore in this clinical scenario?
- A. Presence of coeliac disease affecting insulin absorption
- B. Development of insulin antibodies causing resistance
- C. Psychosocial factors including diabetes burnout and adherence issues (Correct Answer)
- D. Progression to insulin resistance associated with puberty
- E. Malabsorption syndrome reducing carbohydrate intake
Explanation: ***Psychosocial factors including diabetes burnout and adherence issues*** - The patient's parents report he has become more **self-conscious** about injecting insulin and he appears **withdrawn**, strongly suggesting underlying psychological distress and potential **non-adherence** to his insulin regimen. - Adolescence is a common period for **diabetes burnout**, where peer pressure and the desire for normalcy can lead to omitted insulin doses, directly resulting in a rise in **HbA1c**. *Presence of coeliac disease affecting insulin absorption* - While **coeliac disease** is associated with Type 1 Diabetes, it typically causes **malabsorption**, leading to **hypoglycemia** due to reduced carbohydrate absorption, rather than persistent hyperglycemia and rising **HbA1c**. - This diagnosis does not explain the patient's specific **psychological distress** or social anxiety related to insulin injections. *Development of insulin antibodies causing resistance* - Clinically significant **insulin antibody development** causing resistance is extremely rare with modern **recombinant insulin analogues** and is an unlikely cause for the rise in **HbA1c**. - This would also not account for the patient's observed **behavioral changes**, such as self-consciousness and withdrawal. *Progression to insulin resistance associated with puberty* - **Pubertal insulin resistance** is a physiological phenomenon due to hormonal changes, leading to an increased insulin requirement, but it does not explain the **behavioral changes** (self-consciousness, withdrawal) described in the patient. - While it could contribute to difficulty in glycemic control, the psychosocial elements are a more direct and pressing factor given the clinical presentation. *Malabsorption syndrome reducing carbohydrate intake* - A **malabsorption syndrome** would typically result in **hypoglycemia** and often weight loss due to inadequate nutrient absorption, which is contrary to a rising **HbA1c** that indicates chronic hyperglycemia. - The patient's social and emotional symptoms are not consistent with a primary **malabsorption** issue.
Question 47: An 8-year-old girl with epilepsy has been taking sodium valproate for 2 years with excellent seizure control. Her parents bring her to clinic reporting that she has gained 8 kg in weight over the past year, developed increased facial hair, and her scalp hair has become noticeably thinner. Blood tests show normal liver function and full blood count. What is the most appropriate management approach?
- A. Continue sodium valproate and reassure that these are minor side effects
- B. Switch to levetiracetam and discuss that it has fewer metabolic side effects (Correct Answer)
- C. Reduce the dose of sodium valproate by 50%
- D. Add metformin to address the weight gain
- E. Switch to carbamazepine which has a better side effect profile
Explanation: ***Switch to levetiracetam and discuss that it has fewer metabolic side effects***- The patient is experiencing significant **metabolic and cosmetic side effects** of sodium valproate, including **weight gain**, **hirsutism**, and **alopecia** (hair thinning), which necessitate a change in therapy.- **Levetiracetam** is a suitable alternative as it provides broad-spectrum efficacy with a significantly better side effect profile regarding **weight** and **hormonal balance**, preserving seizure control.*Continue sodium valproate and reassure that these are minor side effects*- These side effects are not "minor" as they can significantly impact the patient's **quality of life**, lead to **PCOS-like symptoms**, and reduce **adherence** to treatment.- Ignoring significant weight gain, hirsutism, and hair thinning can have long-term **metabolic and psychosocial consequences** for an 8-year-old girl.*Reduce the dose of sodium valproate by 50%*- Reducing the dose by 50% risks **breakthrough seizures** and loss of excellent seizure control, which is not an acceptable compromise given the availability of alternative AEDs.- Many of valproate's metabolic side effects are not strictly dose-dependent, and a partial reduction may not adequately resolve the **hirsutism** and **weight gain**.*Add metformin to address the weight gain*- Adding **metformin** introduces further polypharmacy and potential **gastrointestinal side effects**, without directly addressing the underlying cause of the valproate-induced metabolic and cosmetic issues.- The primary management strategy for drug-induced adverse effects, especially when significant, is to replace the offending drug rather than treating its **symptoms with additional medications**.*Switch to carbamazepine which has a better side effect profile*- **Carbamazepine** is less suitable for generalized epilepsy as it can worsen some seizure types, and it has its own set of side effects, including **enzyme induction** and potential **weight gain**.- **Levetiracetam** is preferred over carbamazepine in this scenario due to its broader spectrum of activity and superior metabolic and cosmetic side effect profile.
Question 48: What is the recommended target HbA1c for children and young people with type 1 diabetes according to NICE guidelines?
- A. 42 mmol/mol (6.0%) or lower
- B. 48 mmol/mol (6.5%) or lower (Correct Answer)
- C. 53 mmol/mol (7.0%) or lower
- D. 58 mmol/mol (7.5%) or lower
- E. 64 mmol/mol (8.0%) or lower
Explanation: ***48 mmol/mol (6.5%) or lower***- **NICE guidelines** state that the target HbA1c for children and young people with **Type 1 Diabetes** should be 48 mmol/mol (6.5%) or lower to reduce long-term **vascular complications**.- This level is chosen to achieve optimal **glycaemic control** without significantly increasing the risk of severe **hypoglycaemia**.*42 mmol/mol (6.0%) or lower*- This value represents a **non-diabetic** HbA1c range and is generally considered too difficult to maintain for pediatric patients.- Aiming for this level significantly increases the clinical risk of frequent and severe **hypoglycaemic episodes**.*53 mmol/mol (7.0%) or lower*- While this used to be a common target, modern guidelines have lowered the threshold to improve **long-term outcomes** and minimize **microvascular damage**.- This target may only be acceptable if the child has frequent **hypoglycaemic unawareness** or other specific clinical contraindications.*58 mmol/mol (7.5%) or lower*- This was once the standard target for young children to avoid the neurocognitive effects of **hypoglycaemia**.- Subsequent evidence has shown that better health outcomes are achieved with the lower **48 mmol/mol** target without undue harm.*64 mmol/mol (8.0%) or lower*- This level is considered suboptimal and is associated with a significantly increased risk of **retinopathy**, **nephropathy**, and **neuropathy**.- Targets this high are discouraged unless there are severe **psychosocial factors** or comorbidities preventing safer control.
Question 49: A 5-year-old boy with newly diagnosed epilepsy presents to the emergency department with a continuous tonic-clonic seizure lasting 35 minutes. He has received two doses of buccal midazolam (10 mg) by paramedics 10 minutes apart without effect, and one dose of intravenous lorazepam (0.1 mg/kg) 8 minutes ago which also failed to terminate the seizure. Intravenous access is secure. What is the most appropriate next pharmacological intervention?
- A. Give a second dose of intravenous lorazepam 0.1 mg/kg
- B. Commence intravenous phenytoin infusion 20 mg/kg over 20 minutes (Correct Answer)
- C. Give intravenous diazepam 0.25 mg/kg as bolus
- D. Commence intravenous midazolam infusion 0.15 mg/kg/hour
- E. Give rectal paraldehyde 0.4 ml/kg mixed with equal volume of olive oil
Explanation: ***Commence intravenous phenytoin infusion 20 mg/kg over 20 minutes*** - This patient is in **refractory status epilepticus**, having failed initial management with **benzodiazepines**; standard protocols dictate moving to a second-line **antiepileptic drug (AED)** if seizures persist after two doses. - **Phenytoin** (20 mg/kg) or **levetiracetam** are the preferred second-line agents to terminate prolonged seizures when **intravenous access** is established. *Give a second dose of intravenous lorazepam 0.1 mg/kg* - Current guidelines recommend a maximum of **two doses** of benzodiazepines (including pre-hospital buccal midazolam) to avoid **respiratory depression** and because further doses are unlikely to stop the seizure. - This child has already received three benzodiazepine treatments (two buccal, one IV), making further doses inappropriate and delaying **definitive seizure control**. *Give intravenous diazepam 0.25 mg/kg as bolus* - **Diazepam** is another benzodiazepine; switching to a different drug in the same class after several failed attempts is not recommended and increases the risk of **sedation and apnea**. - Management should prioritize a long-acting **loading dose** of an AED like phenytoin rather than repeated short-acting boluses. *Commence intravenous midazolam infusion 0.15 mg/kg/hour* - Continuous **midazolam infusions** are reserved for **third-line management** (refractory status) usually requiring intensive care monitoring and intubation. - It is only indicated after second-line agents like **phenytoin**, **phenobarbital**, or **levetiracetam** have failed to terminate the seizure. *Give rectal paraldehyde 0.4 ml/kg mixed with equal volume of olive oil* - **Rectal paraldehyde** is a historical rescue medication rarely used in modern emergency departments when **intravenous access** is already secured. - It is less effective and more difficult to administer compared to **intravenous phenytoin** or **levetiracetam** in an acute hospital setting.
Question 50: A 14-year-old girl with type 1 diabetes for 6 years presents for annual screening. She is on a basal-bolus regimen with good glycaemic control (HbA1c 52 mmol/mol). Screening reveals an albumin:creatinine ratio (ACR) of 3.5 mg/mmol on a random urine sample. She is asymptomatic and has normal blood pressure. What is the most appropriate next step in management?
- A. Start an ACE inhibitor immediately
- B. Repeat ACR on two further early morning samples within 3-6 months (Correct Answer)
- C. Refer urgently to paediatric nephrology
- D. Increase insulin doses to improve glycaemic control further
- E. Arrange a renal ultrasound scan
Explanation: ***Repeat ACR on two further early morning samples within 3-6 months*** - A single elevated **Albumin:Creatinine Ratio (ACR)** is insufficient for a diagnosis of **microalbuminuria** because transient increases can be caused by exercise, infection, or menstruation. - Guidelines require two out of three **early morning urine samples** to be abnormal over a 3-6 month period to confirm persistent microalbuminuria in diabetic patients. *Start an ACE inhibitor immediately* - **ACE inhibitors** are only indicated once persistent microalbuminuria is confirmed or if the patient develops **hypertension**. - Initiating therapy based on one random sample is premature as the elevation may be **transient** and reversible without medication. *Refer urgently to paediatric nephrology* - Urgent referral is not indicated for an isolated, asymptomatic finding of **microalbuminuria** in a patient with **Stage 1 (Grade 1)** nephropathy screening. - Management initially occurs in the diabetic clinic; referral is reserved for **declining GFR**, hematuria, or failure to respond to standard therapy. *Increase insulin doses to improve glycaemic control further* - The patient's **HbA1c (52 mmol/mol)** is already at a good target level, and aggressive intensification could increase the risk of **hypoglycaemia**. - While glycemic control is vital, the immediate priority for this screening result is to **confirm persistence** of the albuminuria through serial testing. *Arrange a renal ultrasound scan* - A **renal ultrasound** is not part of the standard screening protocol for **diabetic nephropathy**, which is a functional and histological diagnosis rather than structural. - Imaging is typically reserved for cases where there is diagnostic doubt, such as suspected **obstructive uropathy** or atypical kidney size.
Practice by Chapter
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free